Compare Cytokinetics Inc (CYTK) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Alphabet Inc Class A — how do they compare? Cytokinetics Inc trades at $81.56 (market cap $11.12B), while Alphabet Inc Class A trades at $358.36 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 393× Cytokinetics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GOOGL | |
|---|---|---|
Market Cap | $11.12B | $4.37T |
Sector | Technology | Media |
52-Week High | $87.26 | $402.62 |
52-Week Low | $33.23 | $182.00 |
Enterprise Value | $11.59B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Alphabet (GOOGL) trades at $352.51, down 1.31% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 27.42, net income margin of 37.92%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases, while cash flow trends improved to a net positive $7.24B in 2025.
The outlook remains positive with an 85% analyst buy rating and a $431.78 consensus price target, supported by robust revenue growth and AI expansion. Key risks include antitrust scrutiny and market volatility, but the company's financial health and strategic positioning suggest long-term upside for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
